Ophthalmology

Ring Therapeutics signs partnerships to advance R&D in biomedical sciences

Ring Therapeutics has entered into new strategic partnerships with the Agency for Science, Technology, and Research (A*STAR) and the Singapore Eye Research Institute (SERI) to enhance research and development (R&D) efforts in the biomedical sciences sector.

Amgen’s TEPEZZA gets Japan’s MHLW approval for thyroid eye disease treatment

Amgen has announced the receipt of approval from the Japan’s Ministry of Health, Labour and Welfare (MHLW) for TEPEZZA (Teprotumumab) to treat active or high clinical activity score (CAS) thyroid eye disease (TED).

Skyline Therapeutics secures FDA orphan drug status for RP therapy

Skyline Therapeutics has announced that the US Food and Drug Administration (FDA) granted orphan drug designation (ODD) to its gene therapy, SKG1108, for the treatment of Retinitis Pigmentosa (RP), an inherited retinal disease.

Sandoz’s Enzeevu secures FDA approval for nAMD treatment

The US Food and Drug Administration (FDA) has granted approval for Sandoz's Enzeevu (aflibercept-abzv) 2mg vial kit and pre-filled syringe for intravitreal injection, a biosimilar aimed at treating neovascular age-related macular degeneration (nAMD).

Merck enhances ophthalmology portfolio with EyeBio acquisition

MSD (Merck & Co) has completed the acquisition of EyeBio, making it a wholly-owned subsidiary, and bolstering its ophthalmology portfolio.

Beacon Therapeutics secures $170m to expedite gene therapy development

Beacon Therapeutics has announced a successful $170m Series B funding round, led by Forbion, to accelerate the development of its ophthalmic gene therapies, including its lead asset AGTC-501.

FDA approves Formosa-AimMax’s post-surgery eye care treatment

The US Food and Drug Administration (FDA) has granted approval to Formosa Pharmaceuticals and AimMax Therapeutics’ clobetasol propionate ophthalmic suspension 0.05% for post-operative inflammation and pain after ocular surgical procedure.

Entos opens GMP clinical manufacturing facility in US

Entos Pharmaceuticals has inaugurated a new Good Manufacturing Practices (GMP) manufacturing facility in Carlsbad, California in the US.

BlueRock exercises option to license cell therapy candidate

BlueRock Therapeutics has exercised its exclusive option to license induced pluripotent stem cell (iPSC)-derived cell therapy candidate from FUJIFILM Cellular Dynamics and Opsis Therapeutics.